Cold thinking on ten hot issues in the treatment of early breast cancer.
10.3760/cma.j.cn112139-20211010-00482
- Author:
Jian Bin LI
1
;
Ze Fei JIANG
1
Author Information
1. Senior Department of Oncology, the Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100071, China.
- Publication Type:Review
- MeSH:
Breast Neoplasms/drug therapy*;
Disease-Free Survival;
Female;
Humans;
Receptor, ErbB-2/antagonists & inhibitors*
- From:
Chinese Journal of Surgery
2022;60(3):213-218
- CountryChina
- Language:Chinese
-
Abstract:
With the development of new strategies like target therapy and immunotherapy, early breast cancer treatment has become more standardized, and the interval of disease free survival has been extended. Although guidelines and expert consensus have provided supports for clinical decision making, there are still some controversial issues in clinical practice, attributing to different treatment concepts, product indications and accessibility. These controversial issues would eventually affect the treatment of early breast cancer. This year in 2021, the approval of new indications of drugs like abemaciclib and the popularity of dual anti-human epidermal growth factor receptor 2 targeted drugs have promoted the change of treatment modalities for different types of early breast cancer. To this end, ten hot topics of early breast cancer are summarized according to their different molecular typing and treatment stages for discussion.
